Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis

Cardioprotective Effect of β-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy

(2013) Sinziana Seicean et al.   Circulation-Heart Failure

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis

(2013) Kashif Kalam et al.   EUROPEAN JOURNAL OF CANCER

Reply

(2013) Xavier Bosch et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies

(2013) Xavier Bosch et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate

(2013) Mariele Dessì et al.   SpringerPlus

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study

(2012) Mehmet G. Kaya et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Protective Effect of Carvedilol on Adriamycin-Induced Left Ventricular Dysfunction in Children With Acute Lymphoblastic Leukemia

(2012) Nagla A. El-Shitany et al.   JOURNAL OF CARDIAC FAILURE

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2012) Jersey Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial

(2011) Xavier Bosch et al.   JOURNAL OF CARDIAC FAILURE

Beta Blockers and Breast Cancer Mortality: A Population- Based Study

(2011) Thomas I. Barron et al.   JOURNAL OF CLINICAL ONCOLOGY

β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways

(2011) Giovanni Fajardo et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

(2010) Christian Cadeddu et al.   AMERICAN HEART JOURNAL

Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up

(2010) Peter Georgakopoulos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer

(2008) J.-A. W. Chapman et al.   JNCI-Journal of the National Cancer Institute